Chugai Pharmaceutical Co. (OTCMKTS:CHGCY) shares traded down 3.8% during trading on Tuesday . The stock traded as low as $207.33 and last traded at $210.96, 7,329 shares were traded during trading. An increase of 43% from the average session volume of 5,121 shares. The stock had previously closed at $219.32.
Separately, Jefferies Financial Group assumed coverage on Chugai Pharmaceutical in a research report on Monday, December 9th. They set a “buy” rating on the stock.
The firm’s 50 day moving average is $212.49.
Chugai Pharmaceutical Company Profile (OTCMKTS:CHGCY)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.